<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font22 { font-size : 22; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">the </span>
   <span class="font22">and </span>
   <span class="font15">for </span>
   <span class="font14">[]. </span>
   <span class="font14">with </span>
   <span class="font13">are </span>
   <span class="font13">NCT </span>
   <span class="font13">that </span>
   <span class="font13">drug: </span>
   <span class="font13">Phase </span>
   <span class="font12">Drug: </span>
   <span class="font12">have </span>
   <span class="font12">patients </span>
   <span class="font12">has </span>
   <span class="font12">which </span>
   <span class="font12">treatment </span>
   <span class="font12">The </span>
   <span class="font12">SARS-CoV- </span>
   <span class="font12">been </span>
   <span class="font11">NCT, </span>
   <span class="font11">coronavirus </span>
   <span class="font11">viral </span>
   <span class="font11">COVID- </span>
   <span class="font11">virus </span>
   <span class="font11">{background </span>
   <span class="font11">drugs </span>
   <span class="font11">from </span>
   <span class="font11">these </span>
   <span class="font11">can </span>
   <span class="font11">also </span>
   <span class="font11">April </span>
   <span class="font11">clinical </span>
   <span class="font11">plasma </span>
   <span class="font11">hydroxychloroquine </span>
   <span class="font11">margin </span>
   <span class="font11">respiratory </span>
   <span class="font11">against </span>
   <span class="font11">protein </span>
   <span class="font11">was </span>
   <span class="font11">{border-style </span>
   <span class="font11">ACE </span>
   <span class="font11">al. </span>
   <span class="font11">found </span>
   <span class="font11">severe </span>
   <span class="font11">trials </span>
   <span class="font10">This </span>
   <span class="font10">University </span>
   <span class="font10">antiviral </span>
   <span class="font10">placebo </span>
   <span class="font10">px;} </span>
   <span class="font10">#ffffff;} </span>
   <span class="font10">RNA </span>
   <span class="font10">chloroquine </span>
   <span class="font10">use </span>
   <span class="font10">efficacy </span>
   <span class="font10">hydroxychloroquine; </span>
   <span class="font10">its </span>
   <span class="font10">replication </span>
   <span class="font10">syndrome </span>
   <span class="font10">therapeutic </span>
   <span class="font10">this </span>
   <span class="font10">acute </span>
   <span class="font10">disease </span>
   <span class="font10">drug </span>
   <span class="font10">effects </span>
   <span class="font10">human </span>
   <span class="font10">immune </span>
   <span class="font10">potential </span>
   <span class="font10">March </span>
   <span class="font10">RDV </span>
   <span class="font10">not </span>
   <span class="font10">two </span>
   <span class="font10">being </span>
   <span class="font10">cell </span>
   <span class="font10">cells </span>
   <span class="font10">convalescent </span>
   <span class="font10">host </span>
   <span class="font10">inflammatory </span>
   <span class="font10">like </span>
   <span class="font10">receptor </span>
   <span class="font10">May </span>
   <span class="font10">due </span>
   <span class="font10">multiple </span>
   <span class="font10">other </span>
   <span class="font10">studies </span>
   <span class="font10">their </span>
   <span class="font10">important </span>
   <span class="font10">include </span>
   <span class="font10">increased </span>
   <span class="font10">into </span>
   <span class="font10">options </span>
   <span class="font10">protease </span>
   <span class="font10">role </span>
   <span class="font10">standard </span>
   <span class="font10">tocilizumab </span>
   <span class="font10">These </span>
   <span class="font10">infections </span>
   <span class="font10">possible </span>
   <span class="font10">should </span>
   <span class="font10">structural </span>
   <span class="font10">there </span>
   <span class="font10">various </span>
   <span class="font10">viruses </span>
   <span class="font10">Chloroquine </span>
   <span class="font10">Health </span>
   <span class="font10">[], </span>
   <span class="font10">cases </span>
   <span class="font10">dose </span>
   <span class="font10">exchange </span>
   <span class="font10">infection </span>
   <span class="font10">oral </span>
   <span class="font10">phase </span>
   <span class="font10">proteins </span>
   <span class="font10">seen </span>
   <span class="font10">spike </span>
   <span class="font10">such </span>
   <span class="font10">than </span>
   <span class="font10">through </span>
   <span class="font10">Although </span>
   <span class="font10">Coronavirus </span>
   <span class="font10">HIV </span>
   <span class="font10">However, </span>
   <span class="font10">IL-, </span>
   <span class="font10">PLpro </span>
   <span class="font10">SARS-CoV </span>
   <span class="font10">any </span>
   <span class="font10">behind </span>
   <span class="font10">binding </span>
   <span class="font10">combination </span>
   <span class="font10">effective </span>
   <span class="font10">further </span>
   <span class="font10">hospitalized </span>
   <span class="font10">inhibition </span>
   <span class="font10">inhibitor </span>
   <span class="font10">leading </span>
   <span class="font10">most </span>
   <span class="font10">ongoing </span>
   <span class="font10">option </span>
   <span class="font10">px; </span>
   <span class="font10">results </span>
   <span class="font10">risk </span>
   <span class="font10">shown </span>
   <span class="font10">some </span>
   <span class="font10">under </span>
   <span class="font10">were </span>
   <span class="font10">within </span>
   <span class="font10">{font-family </span>
   <span class="font10">Arbidol </span>
   <span class="font10">Biological: </span>
   <span class="font10">Current </span>
   <span class="font10">National </span>
   <span class="font10">Sciences </span>
   <span class="font10">activity </span>
   <span class="font10">blood </span>
   <span class="font10">care </span>
   <span class="font10">cause </span>
   <span class="font10">common </span>
   <span class="font10">could </span>
   <span class="font10">days </span>
   <span class="font10">during </span>
   <span class="font10">enzymes </span>
   <span class="font10">first </span>
   <span class="font10">font-size </span>
   <span class="font10">high </span>
   <span class="font10">including </span>
   <span class="font10">more </span>
   <span class="font10">one </span>
   <span class="font10">other: </span>
   <span class="font10">release </span>
   <span class="font10">reported </span>
   <span class="font10">response </span>
   <span class="font10">resulting </span>
   <span class="font10">therapy </span>
   <span class="font10">they </span>
   <span class="font10">transmission </span>
   <span class="font10">use: </span>
   <span class="font10">when </span>
   <span class="font10">while </span>
   <span class="font10">â€"December </span>
   <span class="font10">â€"September </span>
   <span class="font10">Adverse </span>
   <span class="font10">CLpro </span>
   <span class="font10">COVID-. </span>
   <span class="font10">Drug </span>
   <span class="font10">Gilead </span>
   <span class="font10">June </span>
   <span class="font10">Principle </span>
   <span class="font10">SARS </span>
   <span class="font10">Therefore, </span>
   <span class="font10">adverse </span>
   <span class="font10">antibody </span>
   <span class="font10">approach </span>
   <span class="font10">approved </span>
   <span class="font10">baricitinib </span>
   <span class="font10">biological: </span>
   <span class="font10">caused </span>
   <span class="font10">challenges: </span>
   <span class="font10">coronaviruses </span>
   <span class="font10">cytokine </span>
   <span class="font10">double; </span>
   <span class="font10">effect </span>
   <span class="font10">emerging </span>
   <span class="font10">genomic </span>
   <span class="font10">inhibit </span>
   <span class="font10">mentioned </span>
   <span class="font10">number </span>
   <span class="font10">play </span>
   <span class="font10">promising </span>
   <span class="font10">properties </span>
   <span class="font10">published </span>
   <span class="font10">remdesivir </span>
   <span class="font10">ribavirin </span>
   <span class="font10">showed </span>
   <span class="font10">specific </span>
   <span class="font10">spread </span>
   <span class="font10">still </span>
   <span class="font10">studies, </span>
   <span class="font10">symptoms </span>
   <span class="font10">system </span>
   <span class="font10">targets </span>
   <span class="font10">virus. </span>
   <span class="font10">â€"August </span>
   <span class="font10">â€"July </span>
   <span class="font10">â€"March </span>
   <span class="font10">â€"May </span>
   <span class="font10">COVID-, </span>
   <span class="font10">COVID-: </span>
   <span class="font10">Clinical </span>
   <span class="font10">Dosage: </span>
   <span class="font10">FDA </span>
   <span class="font10">IL- </span>
   <span class="font10">JAK </span>
   <span class="font10">LPV/r </span>
   <span class="font10">MERS </span>
   <span class="font10">Other </span>
   <span class="font10">RdRp </span>
   <span class="font10">SARS-CoV, </span>
   <span class="font10">Since </span>
   <span class="font10">Table </span>
   <span class="font10">Therapeutic </span>
   <span class="font10">[].Â </span>
   <span class="font10">about </span>
   <span class="font10">action </span>
   <span class="font10">active </span>
   <span class="font10">agents </span>
   <span class="font10">anti-inflammatory </span>
   <span class="font10">azithromycin </span>
   <span class="font10">between </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">cells. </span>
   <span class="font10">colchicine </span>
   <span class="font10">components </span>
   <span class="font10">control </span>
   <span class="font10">daily </span>
   <span class="font10">drugs. </span>
   <span class="font10">especially </span>
   <span class="font10">favipiravir </span>
   <span class="font10">few </span>
   <span class="font10">followed </span>
   <span class="font10">glycoprotein </span>
   <span class="font10">had </span>
   <span class="font10">health </span>
   <span class="font10">individuals </span>
   <span class="font10">interactions </span>
   <span class="font10">interleukin- </span>
   <span class="font10">kinase </span>
   <span class="font10">majority </span>
   <span class="font10">may </span>
   <span class="font10">novel </span>
   <span class="font10">outbreak </span>
   <span class="font10">plasma; </span>
   <span class="font10">production </span>
   <span class="font10">proteases </span>
   <span class="font10">receptors </span>
   <span class="font10">recommended </span>
   <span class="font10">regarding </span>
   <span class="font10">review </span>
   <span class="font10">ritonavir </span>
   <span class="font10">sequence </span>
   <span class="font10">signal </span>
   <span class="font10">since </span>
   <span class="font10">site </span>
   <span class="font10">solid; </span>
   <span class="font10">study </span>
   <span class="font10">tablet </span>
   <span class="font10">testing </span>
   <span class="font10">those </span>
   <span class="font10">time </span>
   <span class="font10">used </span>
   <span class="font10">will </span>
   <span class="font10">would </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(COVID-) </span>
   <span class="font10">According </span>
   <span class="font10">Another </span>
   <span class="font10">Baricitinib </span>
   <span class="font10">COVID </span>
   <span class="font10">Cureus </span>
   <span class="font10">Figure </span>
   <span class="font10">Hence, </span>
   <span class="font10">Institute </span>
   <span class="font10">MOA: </span>
   <span class="font10">Medical </span>
   <span class="font10">RBD </span>
   <span class="font10">There </span>
   <span class="font10">Treatment </span>
   <span class="font10">Trial </span>
   <span class="font10">acid </span>
   <span class="font10">administration </span>
   <span class="font10">anakinra </span>
   <span class="font10">applications: </span>
   <span class="font10">based </span>
   <span class="font10">bold </span>
   <span class="font10">both </span>
   <span class="font10">challenging </span>
   <span class="font10">characteristics </span>
   <span class="font10">combined </span>
   <span class="font10">courier; </span>
   <span class="font10">critically </span>
   <span class="font10">cytokines </span>
   <span class="font10">damage </span>
   <span class="font10">data </span>
   <span class="font10">day </span>
   <span class="font10">defined </span>
   <span class="font10">demonstrated </span>
   <span class="font10">diseases </span>
   <span class="font10">dosage </span>
   <span class="font10">doses </span>
   <span class="font10">effects. </span>
   <span class="font10">em; </span>
   <span class="font10">existing </span>
   <span class="font10">explore </span>
   <span class="font10">factor </span>
   <span class="font10">four </span>
   <span class="font10">genetic </span>
   <span class="font10">genome </span>
   <span class="font10">help </span>
   <span class="font10">ill </span>
   <span class="font10">immunomodulatory </span>
   <span class="font10">includes </span>
   <span class="font10">inhibiting </span>
   <span class="font10">inhibitor, </span>
   <span class="font10">inhibitors </span>
   <span class="font10">interaction </span>
   <span class="font10">interest </span>
   <span class="font10">interferon </span>
   <span class="font10">key </span>
   <span class="font10">known </span>
   <span class="font10">large </span>
   <span class="font10">leads </span>
   <span class="font10">limited </span>
   <span class="font10">loading </span>
   <span class="font10">lopinavir </span>
   <span class="font10">lopinavir/ritonavir </span>
   <span class="font10">lung </span>
   <span class="font10">major </span>
   <span class="font10">many </span>
   <span class="font10">membrane </span>
   <span class="font10">new </span>
   <span class="font10">nonstructural </span>
   <span class="font10">origins </span>
   <span class="font10">oxygen </span>
   <span class="font10">participants </span>
   <span class="font10">pathogenesis </span>
   <span class="font10">patient </span>
   <span class="font10">pediatric </span>
   <span class="font10">phosphatase </span>
   <span class="font10">prevention </span>
   <span class="font10">proteins, </span>
   <span class="font10">proteins. </span>
   <span class="font10">pt;} </span>
   <span class="font10">reactions </span>
   <span class="font10">recent </span>
   <span class="font10">remdesivir; </span>
   <span class="font10">research </span>
   <span class="font10">responsible </span>
   <span class="font10">result </span>
   <span class="font10">similar </span>
   <span class="font10">small </span>
   <span class="font10">solution </span>
   <span class="font10">suggested </span>
   <span class="font10">symptomatic </span>
   <span class="font10">systemic </span>
   <span class="font10">treat </span>
   <span class="font10">tried </span>
   <span class="font10">vitro </span>
   <span class="font10">who </span>
   <span class="font10">â€"October </span>
  </p>
 </body>
</html>
